Biomeditsina va amaliyot jurnali, 2022 №2

Subject of the article

EFFECTIVENESS OF COLCHICINE IN PATIENTS WITH COVID-19 (Literature review) (16-22)

Authors

NURALIEVA Dilafruz Mamadiyorovna MUKHAMEDOVA Muyassar Gafurjanovna ISMAILOVA Adolat Abdurakhmanovna

Institution

Center for the Development of Professional Qualifications of Medical Workers

Abstract

The article presents the results of the COLCORONA, KOLORIT, GRECCO-19 studies on the effectiveness of colchicine in the treatment of COVID-19.

Key words

cardiovascular disease (CVD), coronavirus infection COVID-19, colchicine, scale for assessing the clinical condition of the patient -COVID

Literature

Mareev V. Yu., Begrambekova Yu.L., Mareev Yu.V. How evaluate re- sults of treatment in patients with COVID-19? Symptomatic Hospital and Outpatient Clinical Scale for COVID-19 (scale for assessing the clinical condition of the patient -COVID). Kardiologiia. 2020;60(11):35–41. [Russian: Мареев В.Ю., Беграмбекова Ю.Л., Мареев Ю.В. Как оценивать результаты лечения больных с новой коронавирусной инфекцией (COV- ID- 19)? Шкала Оценки Клинического Состояния (ШОКС–КОВИД). Кардиология. 2020;60(11):35-41]. DOI: 10.18087/car- dio.2020.11.n1439 2. Johns Hopkins Coronavirus Resource Center. Mortality Analyses. [In- ternet] Available at: https://coronavirus.jhu.edu/data/mortality 3. Mareev V.Yu., Orlova Ya.A., Pavlikova E.P., Matskeplishvili S.T., Akopyan Zh.A., Plisyk A.G. et al. Combination therapy at an early stage of the novel coronavirus infection (COVID- 19). Case series and design of the clinical trial “BromhexIne and Spironolactone for CoronаvirUs Infection requiring hospiTalization (BISCUIT)”. Kar- diologiia. 2020;60(8):4– 15. [Russian: Мареев В.Ю., Орлова Я.А., Павликова Е.П., Мацкеплишвили С.Т., Акопян Ж.А., Плисюк А.Г. и др. Возможности комбинированной терапии на раннем этапе течения новой коронавирусной инфекции (COVID-19). Разбор клинических случаев и дизайн исследования: Бромгексин И Спиронолактон для лечения КоронаВирусной Инфекции, Требующей госпитализации (БИСКВИТ). Кардиология. 2020;60(8):4–15]. DOI: 10.18087/cardio.2020.8.n1307 4. Mareev V.Yu., Orlova Ya.A., Plisyk A.G., Pavlikova E.P., Matskeplish- vili S.T., Akopyan Zh.A. et al. Results of an open prospective con- trolled comparative study on the treatment of new coronavirus infec- tion (COVID-19): Bromhexine and spironolactone for the treatment of coronavirus Infection requiring hospitalization (BISCUIT). Kardiologiia. 2020;60(11):4–15. [Russian: Мареев В.Ю., Орлова Я.А., Плисюк А.Г., Павликова Е.П., Мацкеплишвили С.Т., Акопян Ж.А. и др. Результаты открытого проспективного контролируемого сравнительного исследования по лечению новой коронавирусной инфекции (COVID- 19): Бромгексин И Спиронолактон для лечения КоронаВирусной Инфекции, Требующей госпитализации (БИСКВИТ). Кардиология. 2020;60(11):4-15]. DOI: 10.18087/ cardio.2020.11.1440 5. Mareev V.Yu., Orlova Ya.A., Pavlikova E.P., Akopyan Zh.A., Matskeplishvili S.T., Plisyk A.G. et al. Proactive anti-inflammatory and anticoagulant therapy in the treatment of advanced stages of nov- el coronavirus infection (COVID-19). Case Series and Study Design: COLchicine versus ruxolitinib and secukinumab in open prospective randomIzed trial (COLORIT). Kardiologiia. 2020;60(9):4–21. [Rus- sian: Мареев В.Ю., Орлова Я.А., Павликова Е.П., Акопян Ж.А., Мацкеплишвили С.Т., Плисюк А.Г. и др. Упреждающая противовоспалительная и антикоагулянтная терапия в лечении продвинутых стадий новой коронавирусной инфекции (COVID-19). Разбор клинических случаев и дизайн исследования: колхицин против руксолитиниба и секукинумаба в открытом проспективном рандомизируемом исследовании у пациентов с COVID-19 (КОЛОРИТ). Кардиология. 2020;60(9):4-21]. DOI: 10.18087/cardio.2020.9.n1338 6. Mareev V.Yu., Orlova Ya.A., Pavlikova E.P., Matskeplishvili S.T., Kras- nova T.N., Malahov P.S. et al. Steroid pulse -therapy in patients With coronAvirus Pneumonia (COVID-19), sYstemic inFlammation And Risk of vEnous thRombosis and thromboembolism (WAYFARER Study). Kardiologiia. 2020;60(6):15–29. [Russian: Мареев В.Ю., Орлова Я.А., Павликова Е.П., Мацкеплишвили С.Т., Краснова Т.Н., Малахов П.С. и др. Пульс- терапия стероидными гормонами больных с коронавирусной пневмонией (COVID-19), системным воспалением и риском венозных тромбозов и тромбоэмболий (исследование ПУТНИК). Кардиология. 2020;60(6):15-29]. DOI: 10.18087/cardio.2020.6.n1226 􀁔􀁛􀁡􀁟􀁘􀁗􀁛􀁩􀁛􀁠􀁓􀀃􀁕􀁓􀀃􀁓􀁟􀁓􀁞􀁛􀇜􀁥􀀃􀁙􀁦􀁣􀁠􀁓􀁞􀁛􀀃􀀃􀂬􀀃􀀃􀁙􀁦􀁣􀁠􀁓􀁞􀀃􀁔􀁛􀁡􀁟􀁘􀁗􀁛􀁩􀁛􀁠􀁮􀀃􀁛􀀃􀁢􀁣􀁓􀁝􀁥􀁛􀁝􀁛􀀃􀀃􀂬􀀃􀀃􀀉􀀎􀀔􀀑􀀍􀉮􀀋􀀃􀀎􀀅􀀃􀉸􀀈􀀎􀀌􀀄􀉖􀀈􀉹􀀈􀀍􀀄􀀃􀉮􀀍􀉖􀀃􀀏􀀑􀉮􀉹􀀓􀀈􀉹􀀄 №2 | 2022 21 7. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello‐Petersen R, Guy- att G, Abeles AM et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research. 2020;72(6):744–60. DOI: 10.1002/acr.24180 8. Kiselev Yu.Yu., Matveev A.V., Sychev D.A. Current and future use of colchicine in patients with COVID-19. Good Clinical Practice. 2020;4S:71–4. [Russian: Киселев Ю.Ю., Матвеев А.В., Сычев Д.А. Возможность и перспективы применения препарата колхицин у пациентов с COVID-19. Качественная Клиническая Практика. 2020;4S:71-4]. DOI: 10.37489/2588-0519-2020-S4-71-74 9. Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial In- farction. New England Journal of Medicine. 2019;381(26):2497–505. DOI: 10.1056/NEJMoa1912388 10. Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ et al. Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. 2020;383(19):1838–47. DOI: 10.1056/ NEJMoa2021372 11. Demidowich AP, Davis AI, Dedhia N, Yanovski JA. Colchicine to de- crease NLRP3-activated inflammation and improve obesity-related metabolic dysregulation. Medical Hypotheses. 2016; 92:67–73. DOI: 10.1016/j.mehy.2016.04.039 12. Yang M, Lv H, Liu Q, Zhang L, Zhang R, Huang X et al. Colchi- cine Alleviates Cholesterol Crystal-Induced Endothelial Cell Py- roptosis through Activating AMPK/SIRT1 Pathway. Oxidative Medicine and Cellular Longevity. 2020; 2020:9173530. DOI: 10.1155/2020/9173530 13. Martínez GJ, Celermajer DS, Patel S. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Atherosclerosis. 2018; 269:262– 71. DOI: 10.1016/j. atherosclerosis.2017.12.027 14. Brunetti L, Diawara O, Tsai A, Firestein BL, Nahass RG, Poiani G et al. Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19. Journal of Clinical Medicine. 2020;9(9):2961. DOI: 10.3390/jcm9092961 15. Montealegre-Gómez G, Garavito E, Gómez-López A, Rojas-Villarra- ga A, Parra-Medina R. Colchicine: A potential therapeutic tool against COVID-19. Experience of 5 patients. Reumatología Clínica. 2020; [Epub ahead of print]. DOI: 10.1016/j.reuma.2020.05.001 16. Lu Y, Chen J, Xiao M, Li W, Miller DD. An Overview of Tubulin Inhib- itors That Interact with the Colchicine Binding Site. Pharmaceutical Research. 2012;29(11):2943–71. DOI: 10.1007/s11095-012-0828-z 17. Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hos- pitalized with Coronavirus Disease 2019: The GRECCO-19 Random- ized Clinical Trial. JAMA Network Open. 2020;3(6): e2013136. DOI: 10.1001/jamanetworkopen.2020.13136 18. University of Oxford. Randomised Evaluation of COVID-19 Therapy. ClinicalTrials.gov Identifier: NCT04381936. Av. at: https://clinical- trials.gov/ct2/show/NCT04381936. 2021. 19. U.S. National Library of Medicine. Anti-Coronavirus Therapies to Prevent Progression of COVID-19, a Randomized Trial. ClinicalTrials. gov Identifier: NCT04324463. Av. at: https://www.clinicaltrials.gov/ ct2/show/NCT04324463. 2020. 20. Tardif J-C, Bouabdallaoui N, L’Allier PL, Gaudet D, Shah B, Pillinger MH et al. Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19. Av. at: http://medrxiv.org/lookup/doi/10.1101/2021.0 1.26.21250494. 2021. 21. Lomonosov Moscow State University Medical Research and Educa- tional Center. COLchicine Versus Ruxolitinib and Secukinumab In Open Prospective Randomized Trial (COLORIT). ClinicalTrials. gov Identifier: NCT04403243. Av. at: https://clinicaltrials.gov/ct2/ show/NCT04403243. 2020. 22. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lympho- cyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Journal of Medical Virol- ogy. 2020;92(10):1733–4. DOI: 10.1002/jmv.25819 23. Royal College of Physicians. National Early Warning Score (NEWS) 2. 2017. [Internet] Available at: https://www.rcplondon.ac.uk/projects/ outputs/national-early-warning-scorenews- 2 24. Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019–2020 epidemic: preparing intensive care units—the ex- perience in Sichuan Province, China. Intensive Care Medicine. 2020;46(2):357–60. DOI: 10.1007/s00134-020-05954-2 25. Landray M. Colchicine for non-hospitalised pts with COVID-19. Av. at: https://twitter.com/MartinLandray/status/13545053885829816 32?s=08. 2021. 26. Ullah W, Basyal B, Tariq S, Almas T, Saeed R, Roomi S et al. Lym- phocyte-to-C-Reactive Protein Ratio: A Novel Predictor of Adverse Outcomes in COVID-19. Journal of Clinical Medicine Research. 2020;12(7):415–22. DOI: 10.14740/jocmr4227 27. Kong M, Zhang H, Cao X, Mao X, Lu Z. Higher level of neutrophil-to- lymphocyte is associated with severe COVID-19. Epidemiology and Infection. 2020;148: e139. DOI: 10.1017/S0950268820001557 28. Karataş MB, İpek G, Onuk T, Güngör B, Durmuş G, Çanga Y et al. As- sessment of Prognostic Value of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Patients with Pulmonary Embo- lism. Acta Cardiologica Sinica. 2016;32(3):313–20. DOI: 10.6515/ acs20151013a 29. Zhang Y, Wu W, Du M, Luo W, Hou W, Shi Y et al. Neutrophil-to- Lymphocyte Ratio may Replace Chest Computed Tomography to Re- flect the Degree of Lung Injury in Patients with Corona Virus Disease 2019 (COVID-19). Av. at: https://www.researchsquare.com/article/ rs- 23201/v1. DOI: 10.21203/rs.3.rs-23201/v1. 2020. 30. Feng Z, Yu Q, Yao S, Luo L, Zhou W, Mao X et al. Early predic- tion of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nature Communications. 2020;11(1):4968. DOI: 10.1038/s41467-020-18786-x 31. Vernadsky R.Yu., Medvedeva A.A., Garbukov E.Yu., Sinilkin I.G., Bragina O.D., Zelchan R.V. et al. Single-photon emission com- puted tomography with 99mTc-1-thio-d-glucose for metabolic breast cancer imaging. Russian Electronic Journal of Radiology. 2019;9(4):82–96. [Russian: Вернадский Р.Ю., Медведева А.А., Гарбуков Е.Ю., Синилкин И.Г., Брагина О.Д., Зельчан Р.В. и др. Метаболическая визуализация рака молочной железы методом однофотонной эмиссионной компьютерной томографии с 99mTc- 1-тио-d-глюкозой. Российский Электронный Журнал Лучевой Диагностики. 2019;9(4):82-96]. DOI: 10.21569/2222-7415-2019- 9-4-82-96